---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021627"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:24:57.785972+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI

## Summary
- LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
- Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.
- Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.
- Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.
- No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide.

## SEC filing metadata
- accession: 0001493152-26-021627
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/0001493152-26-021627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021627
- JSON: https://secwatch.observer/filing/0001493152-26-021627.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.